Gilead Sciences, Inc. v. Apotex Salt Form Patents
Claim 4. Tenofovir alafenamide hemifumarate, having an X-ray powder diffraction (XRPD) pattern that comprises 2theta values of 6.9± 0.2° and 8.6± 0.2°. Claim 6. A composition comprising tenofovir alafenamide hemifumarate according to claim 1, wherein the ratio of fumaric acid to Claim 27. A method for preparing tenofovir alafenamide hemifumarate comprising admixing a) aprotic organic solvent; b) fumaric acid; c) tenofovir alafenamide hemifumarate; and crystallizing additional tenofovir alafenamide hemifumarate. Claim 30. A method for preparing tenofovir alafenamide he...
Source: natlawreview.com